Dry powder inhalers for rescue applications Check out this fascinating article on the potential of Cyclops® for rescue applications, featured in the Inhalation Technology Supplement of the PMPS Spring 2024 edition. Dive into the details through the link below. Don’t miss it!
Check out our scientific poster on Levodopa Cyclops® for the XXIX World Congress on Parkinson’s Disease and Related Disorders 2024! The poster (number: P_05 (GPT)) will be shown on Monday 20 May and presented during the guided poster tour from 03.30 – 04.30 p.m..
Roden, the Netherlands, January 18, 2024 PureIMS, a pharmaceutical company focused on the development of innovative inhalation products, this week reported it has completed a comparative pharmacokinetic study with Levodopa Cyclops®. The study results show rapid pulmonary absorption of levodopa in absence of safety and tolerability issues. These properties make Levodopa Cyclops® a prime candidate […]
Tuesday September 26 was an exciting day for the PureIMS team. Not only was the first cohort of volunteers dosed in the penultimate Levodopa Cyclops™ bioavailability study, we were also honored with the LIFE Science Innovation Award. LIFE Cooperative, very successfully organizing their annual conference and award ceremony, is a cooperation of 50+ LifeScience and MedTech SMEs […]
Following a successful funding round in April of this year (link: successful funding round), PureIMS obtained ethical approval for a pharmacokinetic dose-finding study with its dry powder inhaler lead program Levodopa Cyclops™ and expects to have the study results before the end of 2023. Earlier clinical studies already demonstrated very rapid onset of action, a […]
PureIMS today announced it has secured a new investment round. New investor Boost-UP Foundation has joined current shareholders (CardusoCapital venture capital fund, IMDS Medical Devices and LinesBridge Pharma Group) in this round to finance the company’s ambitious growth strategy. Please find the full press release via this link:
Roden — February 10, 2023 — PureIMS, a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases, has appointed Frank Lambert to the role of Executive Director Commercialization. DPI developer PureIMS has announced the appointment of Frank Lambert as Executive Director Commercialization. The appointment is part of the […]
Check out our scientific poster for DDL2022 on Epinephrine Cyclops™!
PureIMS will be present at the Drug Delivery to the Lungs Conference 2022 in Edinburgh. Please visit our stand (246) and have a chat. We will be more than happy to tell you everything about our Cyclops™ single-use dry powder inhaler and hear all about your interesting projects too! Furthermore, check out our posters on […]
Roden — January 7, 2022 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases has appointed Jaap Wieling to the role of Chief Executive Officer (CEO). Dr. Wieling brings 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research […]
Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com
